Serum endokan düzeyleri ile koroner yavaş akımı ve koroner arter hastalığının ilişkisi
Küçük Resim Yok
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Namık Kemal Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Koroner arter hastalığı (KAH) sık koroner yavaş akım (KYA) ise daha az görülen ve önemli mortalite ve morbitide riski olan kardiyovasküler hastalıklardandır. Her ikisinin risk faktörleri ile benzerdir ve genelikle her ikisinde de mikrovasküler ateroma ve endotelde inflamasyon bulunur. Endokan son yıllarda özelikle bazı inflamatuar hastalıkların yanısıra kardiyovasküler hastalıklarda da araştırılan bir proinflamatuar glikopeptidtir. Bu nedenlerle bizde endokanın benzer popülasyonda hem KAH hem de KYA daki düzeyleri karşılaştırmayı ve endokanın ilave klinik değişkenlerle ilişkisini incelemeyi planladık. Materyal ve Metot: Çalışmaya ardışık olarak koroner anjiografi endikasyonu alan 169 kişiyi çalışmaya dahil ettik. Koroner anjiografi sonucuna göre KAH grubuna 58, KYA grubuna 52 ve kontrol grubuna 59 kişi alındı. Epikardiyal koroner arterlerinde herhangi bir lezyon olmayanlar kontrol grubuna alındı. Tüm hastalarda TIMI- görüntü kare sayıları (TIMI- GKS) hesaplandı. Normalden yavaş olanlar KYA grubuna alındı. En az bir epikardiyal koroner arterde darlık olan hastalar KAH grubuna alındı. Tüm hastaların demografik ve klinik özellikleri kaydedildi. Endokan ve diğer kan analizleri yapıldı. Veriler toplandıktan sonra SPSS ile istatiksel analizler yapıldı. Bulgular: Çalışmamızdaki popülasyonun %2.6 sı KYA na sahipti. Hem KYA( 559 ± 234 pg/ml) hem de KAH grubu (555 ± 223 pg/ml) kontrol grubundan (331± 252 pg/ml) daha yüksek endokan seviyelerine sahipti ( p<0,001). KYA ve KAH grubu arasında benzer endokan seviyeleri vardı. Endokan düzeyleri ortalama TIMI-GKS ile pozitif yönlü korelasyonlu idi (r=0.267; p<0.001). Serum endokan düzeyleri (özellikle ?450 pg/ml'nin üzerindeki değerler) ve hiperlipidemi varlığı kem KYA hemde KAH varlığının ana öngördürücüleri idi. Sonuç: Endokan KAH ve KYA da benzer oranda normale göre yüksektir. Çalışmamızın sonuçları endokanın hem KAH ve hem de KYA nın patofizyolojisinde benzer proinflamatuar özellikler gösterdiğini düşündürtmektedir. Anahtar Kelimeler: Koroner arter hastalığı, koroner yavaş akım, endokan
Aim: Coronary artery disease (CAD) frequent, but coronary slow flow (CSF) are less common cardiovascular diseases with a significant risk of mortality and morbidity. The risk factors for both are similar and generally both have microvascular atheroma and endothelial inflammation. Endocan is a proinflammatory glycopeptide that has been investigated in cardiovascular diseases as well as some inflammatory diseases in recent years. For these reasons, we planned to compare the levels of endocan in both CAD and CSF in a similar population and to examine the relationship of endocan with additional clinical variables. Materials and Methods: In the trial, we included 169 consecutive subjects having a coronary angiography indication. According to the results of coronary angiography, 58 people were included in the CAD group, 52 in the CSF group and 59 people were in the control group. The control group includes those who did not have any lesions in their epicardial coronary arteries. Trombolysis in myocardial infarction (TIMI)-frame counts (TFC) were calculated for all patients. Those who were slower than normal were included in the CSF group. The CAD group includes patients with stenosis (>50%) in at least one epicardial coronary artery. All patients' demographic and clinical features were documented. Endocan and other blood analyzes were performed. Statistical analyzes were performed with SPSS after the data were collected. Results: 2.6% of the population in our study had CSF. Both CAD group (555 ± 223 pg/ml) and CSF (559 ± 234 pg/ml) had higher endocan levels than the control group (331 ± 252 pg/ml) (p<0.001). There were similar endocan levels between the CAD and CSF group. Endocan levels were shown to be favorably associated to mean TFC (r=0.267; p0.001). Serum endocan levels (particularly those above 450 pg/ml) and the presence of hyperlipidemia were the most important predictors of both CAD and CSF. Conclusion: Endocan are similarly higher in CAD and CSF patients than in those with normal coronary artery. According to the findings of our research, endocan has similar proinflammatory properties in the pathophysiology of both CAD and CSF. Keywords: Coronary artery disease, slow coronary flow, endocan
Aim: Coronary artery disease (CAD) frequent, but coronary slow flow (CSF) are less common cardiovascular diseases with a significant risk of mortality and morbidity. The risk factors for both are similar and generally both have microvascular atheroma and endothelial inflammation. Endocan is a proinflammatory glycopeptide that has been investigated in cardiovascular diseases as well as some inflammatory diseases in recent years. For these reasons, we planned to compare the levels of endocan in both CAD and CSF in a similar population and to examine the relationship of endocan with additional clinical variables. Materials and Methods: In the trial, we included 169 consecutive subjects having a coronary angiography indication. According to the results of coronary angiography, 58 people were included in the CAD group, 52 in the CSF group and 59 people were in the control group. The control group includes those who did not have any lesions in their epicardial coronary arteries. Trombolysis in myocardial infarction (TIMI)-frame counts (TFC) were calculated for all patients. Those who were slower than normal were included in the CSF group. The CAD group includes patients with stenosis (>50%) in at least one epicardial coronary artery. All patients' demographic and clinical features were documented. Endocan and other blood analyzes were performed. Statistical analyzes were performed with SPSS after the data were collected. Results: 2.6% of the population in our study had CSF. Both CAD group (555 ± 223 pg/ml) and CSF (559 ± 234 pg/ml) had higher endocan levels than the control group (331 ± 252 pg/ml) (p<0.001). There were similar endocan levels between the CAD and CSF group. Endocan levels were shown to be favorably associated to mean TFC (r=0.267; p0.001). Serum endocan levels (particularly those above 450 pg/ml) and the presence of hyperlipidemia were the most important predictors of both CAD and CSF. Conclusion: Endocan are similarly higher in CAD and CSF patients than in those with normal coronary artery. According to the findings of our research, endocan has similar proinflammatory properties in the pathophysiology of both CAD and CSF. Keywords: Coronary artery disease, slow coronary flow, endocan
Açıklama
Tıp Fakültesi, Kardiyoloji Ana Bilim Dalı
Anahtar Kelimeler
Kardiyoloji, Cardiology
